Yes, they'll be able to offset all losses against future gains. Not to mention they have/will continue to receive R&D govt refunds on that expenditure also.
Keep in mind a lot of the expenditure in the last couple of years has been related to manufacturing the two new CONNEQTproducts; once FDA approval occurs we should see revenues increase significantly from there. I believe the most immediate revenue will be from CONNEQT Pulse and then I imagine that would flow its a bigger, more marketed release of the Band wearable.
Another CR is certainly required to achieve the above, as Craig has mentioned. This hopefully will coincide with a cornerstone US-based investor/s. If we do indeed receive the $5-6m Craig suggested is at contract, CDX could well be in a position to be free from required CRs to fund the core business within 6-12 months.
Given CDX is in growth phase, they will likely run at a loss for the next few years as they inject the lion's share of revenues into scaling the business. That certainly doesn't mean the share price will stay where it is now. Any sniff at revenues above $15-$20m pa will see us north of $1 in the short term IMO.
Add to My Watchlist
What is My Watchlist?
